Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central nervous technique, conolidine modulates alternate molecular targets. A Science Advances research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://eleanord936ziq1.wikigiogio.com/user